ANL vs ZYME vs IMVT vs RCUS vs KYMR vs KO

For growth investors, Zymeworks Inc.

(ZYME) is the stronger pick with 38. 9% revenue growth year-over-year, versus -100. 0% for Adlai Nortye Ltd. (ANL). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate Adlai Nortye Ltd. (ANL) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Zymeworks Inc.

is actually cheaper at 15. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +213. 0%, compared to -39. 7% for Zymeworks Inc. (ZYME). Over 10 years, the gap is even starker: IMVT returned +237. 9% versus ANL's -31. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Arcus Biosciences, Inc. 's 2. 00β — meaning RCUS is approximately -1098% more volatile than KO relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zymeworks Inc.

(ZYME) is pulling ahead at 38. 9% versus -100. 0% for Adlai Nortye Ltd. (ANL). On earnings-per-share growth, the picture is similar: Adlai Nortye Ltd. grew EPS 68. 3% year-over-year, compared to -23. 8% for Kymera Therapeutics, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -833. 1% for Adlai Nortye Ltd. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -996. 4% for ANL. At the gross margin level — before operating expenses — ANL leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Zymeworks Inc.

(ZYME) trades at 15. 5x forward P/E versus 25. 3x for The Coca-Cola Company — 9. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ANL: 151. 9% to $26. 00.

In this comparison, KO (2.

5% yield) pays a dividend. ANL, ZYME, IMVT, RCUS, KYMR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, RCUS: +40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ANL (Healthcare) and ZYME (Healthcare) and IMVT (Healthcare) and RCUS (Healthcare) and KYMR (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ANL is a small-cap quality compounder stock; ZYME is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock; KO is a large-cap quality compounder stock. KO pays a dividend while ANL, ZYME, IMVT, RCUS, KYMR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.